Summarized by Masters of Longevity from PR Newswire.
A biotech conference preview describing a company’s platform technologies and clinical-stage oncology and rare-disease pipeline, useful for potential partners.
Key Takeaways
- ImmunoForge's ELP platform enables sustained subcutaneous drug delivery and can extend circulating half-life up to 200-fold.
- Their LMT blood-brain barrier shuttle selectively targets the Leptin receptor to enhance CNS delivery while reducing peripheral loss.
- Clinical-stage candidates PF1801 and PF1804 hold FDA orphan designations and are positioned for global partnering in Phase 2 programs.
